A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2002
12/28/2002	CA2391205A1 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
12/27/2002	WO2002103031A2 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002	WO2002103024A2 Stabilized proteins with engineered disulfide bonds
12/27/2002	WO2002103014A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
12/27/2002	WO2002103004A1 Surface modification for improving biocompatibility
12/27/2002	WO2002102997A2 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/27/2002	WO2002102990A2 Fibroblast growth factor and nucleic acid encoding same
12/27/2002	WO2002102987A2 Methods and compositions based on protein interactions with mastermind
12/27/2002	WO2002102982A2 Hoxd3 compositions ad methods for improved wound healing
12/27/2002	WO2002102973A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
12/27/2002	WO2002102972A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
12/27/2002	WO2002102854A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
12/27/2002	WO2002102846A2 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
12/27/2002	WO2002102840A2 Multiners of class i major histocompatibility complexes cantaining modified beta2-microglobulin proteins
12/27/2002	WO2002102828A2 Chimeric flavivirus vectors
12/27/2002	WO2002102825A2 Fluorescently labelled locked nucleic acids
12/27/2002	WO2002102417A1 Vector and the use thereof in gene therapy methods
12/27/2002	WO2002102412A2 Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
12/27/2002	WO2002102404A1 Uses of cytokines
12/27/2002	WO2002102319A2 Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue
12/27/2002	WO2002102310A2 Proteins associated with cell growth, differentiation, and death
12/27/2002	WO2002102306A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002	WO2002102229A2 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002	WO2002083909A3 Recombinant nucleotide sequence coding for a gene
12/27/2002	WO2002072852A3 Leporipox-based vector vaccines
12/27/2002	WO2002066620A3 Pigmentary epithelium cell of the eye, the production thereof and the use of the same for treating diseases of the eye or of the central nervous system
12/27/2002	WO2002066072A9 Methods for the treatment and diagnosis of prostate cancer based on p75ntr tumor
12/27/2002	WO2002057461A3 Regulation of human adam-ts-like zinc metalloprotease
12/27/2002	WO2002057415A3 Method for altering cell fate
12/27/2002	WO2002057302A3 A virus causing respiratory tract illness in susceptible mammals
12/27/2002	WO2002051994A3 Polypeptides
12/27/2002	WO2002049676A3 Compositions containing inclusion complexes
12/27/2002	WO2002042452A3 Adapter protein and gene encoding it
12/27/2002	WO2002029065A3 Retroviral vectors containing internal ribosomal entry sites
12/27/2002	WO2002024908A9 Novel tissue-specific secretory polypeptide and dna thereof
12/27/2002	WO2002024234A3 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
12/27/2002	WO2002016593A3 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
12/27/2002	WO2002010379B1 Modified cea and uses thereof
12/27/2002	WO2002004623A3 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
12/27/2002	WO2002004514A8 Compositions and methods for the therapy and diagnosis of lung cancer
12/27/2002	WO2002000877A3 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis
12/27/2002	WO2001091699A3 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
12/27/2002	WO2001087935A9 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
12/27/2002	WO2001083715A8 Derivation of midbrain dopaminergic neurons from embryonic stem cells
12/27/2002	WO2001081404A3 INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF
12/27/2002	WO2001074903A9 Cd20/ige-receptor like molecules and uses thereof
12/27/2002	WO2001074861A9 Compositions and methods for tissue specific gene regulation therapy
12/27/2002	WO2001052904A9 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
12/27/2002	WO2001021767A9 Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
12/27/2002	WO2000052184A9 Anti-neoplastic compositions and uses thereof
12/27/2002	CA2451874A1 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
12/27/2002	CA2450847A1 Novel compositions
12/27/2002	CA2450845A1 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
12/27/2002	CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002	CA2450793A1 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
12/27/2002	CA2450732A1 Stabilized proteins with engineered disulfide bonds
12/27/2002	CA2450666A1 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002	CA2450590A1 Methods and compositions for inhibiting, preventing or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002	CA2450127A1 Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue
12/27/2002	CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002	CA2448971A1 Chimeric flavivirus vectors
12/27/2002	CA2446285A1 Fibroblast growth factor and nucleic acid encoding same
12/27/2002	CA2430627A1 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/26/2002	US20020198509 Intradermal delivery of vaccines and gene therapeutic agents via microcannula
12/26/2002	US20020198367 DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof
12/26/2002	US20020198211 cDNA for human methylenetetrahydrofolate reductase and uses thereof
12/26/2002	US20020198167 Transfecting an ovarian tumor cell with a vector encoding human UDP-glucuronosyltransferase 2B7, wherein constant or temporal expression of UDP-glucuronosyltransferase 2B7 in that cell results growth arrest of tumor cells
12/26/2002	US20020198166 Method for treatment of cancer and infectious diseases and compositions useful in same
12/26/2002	US20020198164 A toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence
12/26/2002	US20020198151 Intracellular inhibitors of Gq protein signaling
12/26/2002	US20020198144 MHC molecule that contains a peptide-binding groove, and a presenting peptide covalently linked to the MHC molecule, the fusion complex being capable of modulating the activity of a T cell.
12/26/2002	US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/26/2002	US20020197720 Transfecting of preferential cells; provide immobilized transfection complex, incubate with cells, recover transfected cells
12/26/2002	US20020197700 Receptor of the EDb-fibronectin domains
12/26/2002	US20020197684 Ribozymes; for use as amplification tools in genetic engineering
12/26/2002	US20020197681 Identification and uses of a hyaluronan receptor for endocytosis
12/26/2002	US20020197680 54420, a novel human calcium channel
12/26/2002	US20020197660 Novel molecules of the PYRIN domain protein family and uses thereof
12/26/2002	US20020197602 Nucleic acid sequences and proteins associated with aging
12/26/2002	US20020197599 Novel adjuvants and copolymer compositions
12/26/2002	US20020197270 Immunogenic compositions for induction of anti-tumor immunity
12/26/2002	US20020197266 Immunotherapy using interleukin 13 receptor subunit alpha 2
12/26/2002	US20020197265 Methods and compounds for the treatment of immunologically - mediated diseases of the respiratory system using mycobacterium vaccae
12/26/2002	US20020197237 Adeno-associated virus vectors
12/26/2002	US20020197236 Treatment of deseases by site specific instillation of cells or sitespecific transformation of cells and kits therefor
12/26/2002	US20020197232 Methods for using the obese gene and its gene product to stimulate hematopoietic development
12/26/2002	CA2391568A1 Collapsin response mediator protein-1
12/25/2002	CN1387576A Sequence-specific DNA recombination in ekaryotic cells
12/25/2002	CN1387575A Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
12/25/2002	CN1387569A Apoptin-associating protein
12/25/2002	CN1387537A Pharmaceutical compositions and methods of using secreted frizzled related protein
12/25/2002	CN1387442A Oral recombinant lactobacilli vaccines
12/25/2002	CN1386548A Process for preparing transgenic compound particles of alkylated chitosan
12/24/2002	US6498234 Compounds
12/24/2002	US6498233 Nucleic acid transfer system
12/24/2002	US6498147 Suppression of nuclear factor-κb dependent processes using oligonucleotides
12/24/2002	US6498144 Enhancing wound healing and organ transplantation
12/24/2002	US6498035 Antisense modulation of MEKK3 expression
12/24/2002	US6498033 Retroviral vector with gag gene sequence containing packaging signal; human immunodeficiency virus treatment; vaccines; gene therapy; anticarcinogenic agents
12/24/2002	US6498027 Virus-like particle or gene delivery vehicle

1 ... 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 ... 870